-

LYSOGENE Releases the Results From June 26, 2020 Ordinary Annual and Extraordinary General Meeting

  • Shareholders approved all proposed resolutions

PARIS--(BUSINESS WIRE)--Regulatory News:

Lysogene (FR0013233475-LYS) (Paris:LYS) held its ordinary annual and extraordinary general meeting of shareholders on June 26, 2020, in closed session, which was chaired by Karen Aiach, Chairman of the Board of directors and chief executive officer, without the physical presence of the shareholders.

With a quorum of 53.64%, the shareholders have adopted all the resolutions recommended by the Board of Directors, including the financial statements for the 2019 financial year, the compensation policy applicable to the Chairman and Chief Executive Officer and the directors, as well as delegations granted to the Board of Directors related to financial transactions.

Shareholders also approved the renewal of Karen Aiach, Philippe Goupit, Peter Lichtlen, David Schilansky, Mathieu Simon and Carole Deffez as Board members.

Details on the vote results will be available on the company’s website.

About Lysogene
Lysogene is a gene therapy company focused on the treatment of orphan diseases of the central nervous system (CNS). The company has built a unique capability to enable a safe and effective delivery of gene therapies to the CNS to treat lysosomal diseases and other genetic disorders of the CNS. A phase 2/3 clinical trial in MPS IIIA in partnership with Sarepta Therapeutics, Inc. is ongoing and a phase 1/3 clinical trial in GM1 gangliosidosis is in preparation. In accordance with the agreements signed between Lysogene and Sarepta Therapeutics, Inc., Sarepta Therapeutics, Inc. will hold exclusive commercial rights to LYS-SAF302 in the United States and markets outside Europe; and Lysogene will maintain commercial exclusivity of LYS-SAF302 in Europe. Lysogene is also collaborating with an academic partner to define the strategy of development for the treatment of Fragile X syndrome, a genetic disease related to autism. www.lysogene.com.

Contacts

Stéphane Durant des Aulnois
Chief Financial Officer
stephane.durant-des-aulnois@lysogene.com
+ 33 1 41 43 03 99

LYSOGENE

BOURSE:LYS
Release Versions
EnglishFrench

Contacts

Stéphane Durant des Aulnois
Chief Financial Officer
stephane.durant-des-aulnois@lysogene.com
+ 33 1 41 43 03 99

More News From LYSOGENE

Lysogene Reports Full Year 2021 Financial Results

PARIS--(BUSINESS WIRE)--Regulatory News: Lysogene (FR0013233475 – LYS), a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases, today reports its 2021 full-year financial results, approved by the Board of Directors on 30 March 2022. Audit procedures on the Company’s 2021 financial statements were completed by the Company’s statutory auditors. Karen Aiach, Founder, Chairman and Chief Executive Officer of Lysogene, said: “In 2021, Lysogene initiated a second clini...

Lysogene Provides Update on Efficacy, Safety and Timelines of the AAVance Phase 2/3 Clinical Trial with Gene Therapy LYS-SAF302 for the Treatment of MPSIIIA

PARIS--(BUSINESS WIRE)--Regulatory News: Lysogene (FR0013233475 – LYS), a phase 3 gene therapy platform company targeting central nervous system (CNS) diseases, today provides an update on clinical results and timelines of the ongoing AAVance phase 2/3 clinical trial with the investigational gene therapy LYS-SAF302 for the treatment of MPS IIIA (NCT03612869). AAVance is an open-label single-arm multicenter trial aimed at evaluating the effectiveness of a one-time intracerebral delivery of a rec...

Lysogene Reports Additional Positive Biomarker Data With LYS-SAF302 and Favorable Safety Data With LYS-GM101 Presented at the WORLDSymposium™ 2022

PARIS--(BUSINESS WIRE)--Regulatory News: Lysogene (FR0013233475 – LYS), a phase 3 gene therapy platform company targeting central nervous system (CNS) diseases, today reports positive biomarker data from the ongoing AAVance clinical trial with LYS-SAF302 for the treatment of MPS IIIA (NCT03612869) as well as favorable safety data from the ongoing adaptative clinical trial with LYS-GM101 for the treatment of GM1 gangliosidosis (NCT04273269). Data were presented in oral presentations at the WORLD...
Back to Newsroom